LOTUSEYE

Lotus Eye Hospital and Institute Share Price

₹66.92 +0.73 (1.1%)

28 Dec, 2024 01:10

SIP TrendupStart SIP in LOTUSEYE

Start SIP

Performance

  • Low
  • ₹65
  • High
  • ₹68
  • 52 Week Low
  • ₹49
  • 52 Week High
  • ₹96
  • Open Price₹68
  • Previous Close₹66
  • Volume10,310

Investment Returns

  • Over 1 Month -3.81%
  • Over 3 Month -16.14%
  • Over 6 Month + 13.89%
  • Over 1 Year -20.1%
SIP Lightning

Smart Investing Starts Here Start SIP with Lotus Eye Hospital and Institute for Steady Growth!

Invest Now

Lotus Eye Hospital and Institute Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 98.9
  • PEG Ratio
  • -1.5
  • Market Cap Cr
  • 139
  • P/B Ratio
  • 2.3
  • Average True Range
  • 3.49
  • EPS
  • 0.69
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.08
  • RSI
  • 39.26
  • MFI
  • 50.38

Lotus Eye Hospital and Institute Financials

Lotus Eye Hospital and Institute Technicals

EMA & SMA

Current Price
₹66.92
+ 0.73 (1.1%)
pointer
  • stock-down_img
  • Bullish Moving Average 1
  • stock-up_img
  • Bearish Moving Average 15
  • 20 Day
  • ₹69.97
  • 50 Day
  • ₹70.59
  • 100 Day
  • ₹70.48
  • 200 Day
  • ₹70.63

Resistance and Support

66.64 Pivot Speed
  • R3 70.98
  • R2 69.44
  • R1 68.18
  • S1 65.38
  • S2 63.84
  • S3 62.58

What's your outlook on Lotus Eye Hospital and Institute?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lotus Eye Hospital And Institute has an operating revenue of Rs. 48.72 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 8% is okay, ROE of 4% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 27% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 34 which is a POOR score indicating inconsistency in earnings, a RS Rating of 29 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 29 indicates it belongs to a strong industry group of Medical-Hospitals and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lotus Eye Hospital and Institute Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2023-08-14 Quarterly Results
2023-05-24 Audited Results & Dividend
2023-02-13 Quarterly Results
2022-11-14 Audited Results
Date Purpose Remarks
2022-09-10 FINAL Rs.0.50 per share(5%)Final Dividend

Lotus Eye Hospital and Institute F&O

Lotus Eye Hospital and Institute Shareholding Pattern

40.03%
0%
42.84%
17.13%

About Lotus Eye Hospital and Institute

  • NSE Symbol
  • LOTUSEYE
  • BSE Symbol
  • 532998
  • Managing Director
  • Ms. Sangeetha Sundaramoorthy
  • ISIN
  • INE947I01017

Similar Stocks to Lotus Eye Hospital and Institute

Lotus Eye Hospital and Institute FAQs

Lotus Eye Hospital and Institute share price is ₹66 As on 28 December, 2024 | 00:56

The Market Cap of Lotus Eye Hospital and Institute is ₹139.2 Cr As on 28 December, 2024 | 00:56

The P/E ratio of Lotus Eye Hospital and Institute is 98.9 As on 28 December, 2024 | 00:56

The PB ratio of Lotus Eye Hospital and Institute is 2.3 As on 28 December, 2024 | 00:56

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23